clarithromycin has been researched along with itraconazole in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (13.51) | 18.2507 |
| 2000's | 10 (27.03) | 29.6817 |
| 2010's | 16 (43.24) | 24.3611 |
| 2020's | 6 (16.22) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Casciano, CN; Clement, RP; Johnson, WW; Wang, EJ | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Oster, G; Thompson, D | 1 |
| de'Clari, F | 1 |
| Demetris, AJ; Gritsch, A; Jordan, M; Katari, SR; Magnone, M; McCauley, J; Randhawa, PS; Scantlebury, V; Shapiro, R; Starzl, T; Vivas, C | 1 |
| Auclair, B; Berning, SE; Huitt, GA; Peloquin, CA | 1 |
| Ahonen, J; Jokinen, MJ; Neuvonen, PJ; Olkkola, KT | 1 |
| Cheng, B | 1 |
| Dige-Petersen, H; Koch, C; Lanng, S; Main, KM; Müller, J; Sillesen, IB; Skov, M | 1 |
| De Schepper, J; De Schutter, I; De Wachter, E; Malfroot, A; Vanbesien, J | 1 |
| Jacobson, TA | 1 |
| Aihara, K; Fukui, M; Ishitoko, M; Itotani, R; Kagioka, H; Matsumoto, M; Suzuki, S; Takemura, M | 1 |
| Chang, SE; Choi, JH; Kim, JE; Kim, MN; Lee, MW; Moon, KC; Sung, H; Won, CH | 1 |
| Benchikhi, H; Hali, F; Khadir, K; Marouane, S; Ouakadi, A; Radouane, N; Soussi, M; Zamiati, S | 1 |
| Hall, SD; Higgins, JW; Ke, AB; Zamek-Gliszczynski, MJ | 1 |
| Higgins, JW; Ke, AB; Zamek-Gliszczynski, MJ | 1 |
| Bleier, BS; Han, X; Hoang, JD; Lam, A; Singleton, A | 1 |
| Zhang, T | 1 |
| Buckley, DB; Isringhausen, CD; Ogilvie, BW; Vermeer, LM | 1 |
| Daali, Y; Desmeules, JA; Marsousi, N; Rudaz, S | 1 |
| Britz, H; Eissing, T; Frechen, S; Hanke, N; Lehr, T; Moj, D; Wendl, T | 1 |
| Ghadiri, M; Lee, WH; Leong, CR; Loo, CY; Traini, D; Young, PM | 1 |
| Cahn, AP; Georgiou, A; Harrell, AW; Hessel, EM; Marotti, M; Patel, A; Riddell, K; Taskar, KS; Taylor, M; Tracey, H; Wilson, R | 1 |
| Chindamporn, A; Chuleerarux, N; Manothummetha, K; Permpalung, N; Plongla, R; Torvorapanit, P; Worasilchai, N | 1 |
| Dickinson, GL; Hall, SD; Kulanthaivel, P; Morse, BL; Posada, MM; Turner, PK | 1 |
| Chaturvedula, A; Cicali, B; Cristofoletti, R; Hoechel, J; Lingineni, K; Schmidt, S; Vozmediano, V; Wendl, T; Wiesinger, H | 1 |
| Hayashi, N; Hirama, T; Kikuchi, M; Kumondai, M; Maekawa, M; Mano, N; Mizuguchi, A; Okada, Y; Sato, T; Sato, Y; Ui, M | 1 |
| Cui, X; Guo, M; Li, D; Yan, C; Zhang, Y; Zhao, Y | 1 |
2 review(s) available for clarithromycin and itraconazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The potential to treat lung cancer via inhalation of repurposed drugs.
Topics: Administration, Inhalation; Antineoplastic Agents; Clarithromycin; Drug Repositioning; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Itraconazole; Lung Neoplasms | 2018 |
3 trial(s) available for clarithromycin and itraconazole
| Article | Year |
|---|---|
Effect of clarithromycin and itraconazole on the pharmacokinetics of ropivacaine.
Topics: Administration, Oral; Adult; Amides; Anesthetics, Local; Area Under Curve; Clarithromycin; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Humans; Injections, Intravenous; Itraconazole; Male; Protein Synthesis Inhibitors; Ropivacaine | 2001 |
Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
Topics: Adolescent; Adult; Anticholesteremic Agents; Antiprotozoal Agents; Area Under Curve; Atorvastatin; Biomarkers; Calcium Channel Blockers; Clarithromycin; Creatine Kinase; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Itraconazole; Male; Mibefradil; Middle Aged; Pravastatin; Protein Synthesis Inhibitors; Pyrroles; Simvastatin; Verapamil | 2004 |
Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Area Under Curve; Clarithromycin; Computer Simulation; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Erythromycin; Healthy Volunteers; Humans; Indazoles; Indoles; Itraconazole; Male; Microsomes, Liver; Midazolam; Middle Aged; Models, Biological; Oxazoles; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Prospective Studies; Retrospective Studies; Young Adult | 2020 |
32 other study(ies) available for clarithromycin and itraconazole
| Article | Year |
|---|---|
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
Topics: 3T3 Cells; Adrenergic Uptake Inhibitors; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Biological Transport, Active; Cell Line; Cell Separation; Cell Survival; Flow Cytometry; Fluorescent Dyes; Humans; Inhibitory Concentration 50; Mice; Protein Binding; Reserpine; Spectrometry, Fluorescence; Substrate Specificity; Time Factors | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Use of terfenadine and contraindicated drugs.
Topics: Anti-Bacterial Agents; Antifungal Agents; Clarithromycin; Contraindications; Drug Interactions; Drug Utilization; Erythromycin; Histamine H1 Antagonists; Humans; Itraconazole; Ketoconazole; Pharmaceutical Services; Product Labeling; Retrospective Studies; Terfenadine; Troleandomycin | 1996 |
Ciprofloxacin was the culprit--not itraconazole.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Bronchodilator Agents; Central Nervous System; Ciprofloxacin; Clarithromycin; Drug Interactions; Drug Therapy, Combination; Humans; Itraconazole; Theophylline; Time Factors | 1997 |
Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Antifungal Agents; Biopsy, Needle; Clarithromycin; Creatinine; Diltiazem; Drug Interactions; Female; Humans; Hyperglycemia; Hyperkalemia; Hypertension; Immunosuppressive Agents; Infusions, Intravenous; Itraconazole; Kidney; Kidney Transplantation; Male; Middle Aged; Tacrolimus; Time Factors; Transplantation, Homologous; Tremor; Ultrasonography; Vasodilator Agents | 1997 |
Potential interaction between itraconazole and clarithromycin.
Topics: Adult; Anti-Bacterial Agents; Antifungal Agents; Aspergillosis; Clarithromycin; Drug Interactions; Drug Therapy, Combination; Female; Humans; Itraconazole; Lung Diseases, Fungal; Male; Middle Aged; Mycobacterium avium-intracellulare Infection | 1999 |
Preventing opportunistic infections.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Clarithromycin; Clindamycin; Clinical Trials as Topic; Clotrimazole; Cytomegalovirus Infections; Dapsone; Fluconazole; Ganciclovir; Humans; Itraconazole; Leucovorin; Mycobacterium avium-intracellulare Infection; Mycoses; Pentamidine; Pneumonia, Pneumocystis; Pyrimethamine; Rifabutin; Toxoplasmosis; Trimethoprim, Sulfamethoxazole Drug Combination; Valacyclovir; Valine | 1995 |
Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient.
Topics: Adult; Anti-Inflammatory Agents; Aspergillosis, Allergic Bronchopulmonary; Budesonide; Clarithromycin; Cushing Syndrome; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Follow-Up Studies; Humans; Itraconazole; Risk Assessment | 2002 |
Inhaled budesonide induced Cushing's syndrome in cystic fibrosis patients, due to drug inhibition of cytochrome P450.
Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antifungal Agents; Aspergillosis, Allergic Bronchopulmonary; Aspergillus fumigatus; Bronchodilator Agents; Budesonide; Clarithromycin; Cushing Syndrome; Cystic Fibrosis; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Synergism; Drug Therapy, Combination; Escherichia coli Infections; Fatal Outcome; Female; Humans; Iatrogenic Disease; Infant, Newborn; Itraconazole; Lung Diseases; Male; Mycobacterium Infections, Nontuberculous | 2003 |
[Case of bronchocentric granulomatosis that became recognized in the course of allergic bronchopulmonary aspergillosis].
Topics: Antifungal Agents; Aspergillosis, Allergic Bronchopulmonary; Bronchial Diseases; Clarithromycin; Drug Therapy, Combination; Echinocandins; Granuloma; Humans; Itraconazole; Lipopeptides; Lipoproteins; Macrolides; Male; Methylprednisolone; Micafungin; Middle Aged; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Synchronous infection with Mycobacterium chelonae and Paecilomyces in a heart transplant patient.
Topics: Adult; Anti-Bacterial Agents; Antifungal Agents; Biopsy; Clarithromycin; Dermatomycoses; Drug Therapy, Combination; Heart Transplantation; Humans; Itraconazole; Leg; Male; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Paecilomyces; Skin Diseases, Bacterial; Thumb | 2011 |
[Generalized chromomycosis caused by Phialophora verrucosa].
Topics: Adult; Amphotericin B; Antifungal Agents; Arm; Chromoblastomycosis; Clarithromycin; Diabetes Complications; Diagnosis, Differential; Female; Hand Dermatoses; Humans; Itraconazole; Leishmaniasis, Cutaneous; Morocco; Naphthalenes; Phialophora; Terbinafine; Tuberculosis, Cutaneous | 2013 |
Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies.
Topics: Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Databases, Factual; Drug Design; Drug Interactions; Enzyme Inhibitors; Europe; Humans; Itraconazole; Ketoconazole; United States; United States Food and Drug Administration | 2014 |
Clinical CYP3A inhibitor alternatives to ketoconazole, clarithromycin and itraconazole, are not transported into the liver by hepatic organic anion transporting polypeptides and organic cation transporter 1.
Topics: Animals; Clarithromycin; Cytochrome P-450 CYP3A Inhibitors; Itraconazole; Ketoconazole; Liver; Male; Mice; Mice, Knockout; Organic Anion Transporters; Organic Cation Transporter 1 | 2014 |
Itraconazole and clarithromycin inhibit P-glycoprotein activity in primary human sinonasal epithelial cells.
Topics: Anti-Bacterial Agents; Antifungal Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Clarithromycin; Dibenzocycloheptenes; Dose-Response Relationship, Drug; Epithelial Cells; Fluoresceins; Fluorescent Dyes; Humans; Itraconazole; Paranasal Sinuses; Quinolines; Th2 Cells | 2015 |
Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites.
Topics: Area Under Curve; Atorvastatin; Cimetidine; Clarithromycin; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Itraconazole; Models, Biological; Phenytoin; Rifampin | 2015 |
Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters.
Topics: Biological Transport; Cell Line; Clarithromycin; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; HEK293 Cells; Humans; Itraconazole; Ketoconazole; Membrane Transport Proteins; Ritonavir | 2016 |
Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software.
Topics: Ciprofloxacin; Clarithromycin; Computer Simulation; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inducers; Drug Interactions; Fluconazole; Humans; Itraconazole; Ketoconazole; Models, Biological; Paroxetine; Quinidine; Rifampin; Software | 2018 |
PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.
Topics: Alfentanil; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clarithromycin; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Humans; Itraconazole; Midazolam; Models, Biological; Rifampin | 2018 |
Topics: Anti-Bacterial Agents; Antifungal Agents; Antiparasitic Agents; Azithromycin; Clarithromycin; Doxycycline; Humans; Itraconazole; Macrolides; Parasitic Sensitivity Tests; Pythiosis; Pythium; Terbinafine; Tetracyclines; Thailand | 2020 |
Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling.
Topics: Administration, Oral; Adult; Aged; Alkynes; Aminopyridines; Area Under Curve; Benzimidazoles; Benzoxazines; Bosentan; Clarithromycin; Computer Simulation; Cyclin-Dependent Kinases; Cyclopropanes; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Diltiazem; Drug Interactions; Female; Healthy Volunteers; Humans; Itraconazole; Ketoconazole; Male; Middle Aged; Modafinil; Models, Biological; Rifampin; Verapamil | 2020 |
Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling.
Topics: Adult; Alkynes; Benzoxazines; Body Mass Index; Carbamazepine; Clarithromycin; Computer Simulation; Contraceptives, Oral, Combined; Cyclopropanes; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Combinations; Drug Interactions; Ethinyl Estradiol; Female; Humans; Itraconazole; Levonorgestrel; Models, Biological; Obesity; Rifampin; Sex Hormone-Binding Globulin | 2021 |
Therapeutic Drug Monitoring of Blood Sirolimus and Tacrolimus Concentrations for Polypharmacy Management in a Lymphangioleiomyomatosis Patient Taking Two Cytochrome P450 3A Inhibitors.
Topics: Clarithromycin; Cytochrome P-450 CYP3A; Drug Monitoring; Female; Humans; Immunosuppressive Agents; Itraconazole; Lymphangioleiomyomatosis; Middle Aged; Mycophenolic Acid; Polypharmacy; Prednisolone; Sirolimus; Tacrolimus | 2023 |
Evidence of potential pro-haemorrhagic drug interactions between CYP3A4 inhibitors and direct oral anticoagulants: Analysis of the FAERS database.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Bacterial Agents; Anticoagulants; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Hemorrhage; Humans; Itraconazole | 2023 |